LIP
VRDN icon

Lighthouse Investment Partners’s Viridian Therapeutics VRDN Stock Holding History

Lighthouse Investment Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-28,406
Closed -$497K – 550
2024
Q1 		$497K Buy
+28,406
New +$551K 0.02% 331

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Lighthouse Investment Partners's VRDN Position: Q2 2024 in Review

Lighthouse Investment Partners sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 28,406 shares — an estimated $497K sold.

Lighthouse Investment Partners first reported a position in VRDN in Q1 2024 and held it in 1 quarter. The position peaked at $497K in Q1 2024. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Lighthouse Investment Partners reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lighthouse Investment Partners sold 28,406 Viridian Therapeutics shares in Q2 2024, an estimated $497K.
  • Lighthouse Investment Partners first reported a position in Viridian Therapeutics in Q1 2024 and held it in 1 quarter.
  • Lighthouse Investment Partners's Viridian Therapeutics position peaked at $497K in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Lighthouse Investment Partners's 13F filing for Q2 2024, filed 14 Aug 2024.